Form 4: Akero Therapeutics CSO Executes Planned Stock Option Exercise and Share Sale

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, exercised stock options and subsequently sold an equivalent number of shares on July 7, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, Inc. (AKRO), executed transactions on July 7, 2025.
• Rolph acquired 12,500 shares of Common Stock by exercising stock options at a price of $21.09 per share.
• Concurrently, Rolph disposed of a total of 12,500 shares of Common Stock through multiple sales.
• The sales included 10,634 shares at a weighted-average price of $50.932, with prices ranging from $50.595 to $51.59.
• An additional 1,825 shares were sold at a weighted-average price of $51.996, with prices ranging from $51.61 to $52.53.
• A further 41 shares were sold at a weighted-average price of $52.617, with prices ranging from $52.61 to $52.67.
• All reported transactions were conducted pursuant to a Rule 10b5-1 trading plan established on August 12, 2024.
• Following these transactions, Timothy Rolph beneficially owns 167,124 shares of Common Stock.
• Rolph also holds 19,933 derivative securities in the form of stock options, which are vested and currently exercisable.

Sentiment

Score: 7

Explanation: The transaction is a routine insider stock option exercise and subsequent sale under a pre-arranged 10b5-1 plan. The insider profited significantly from the exercise and sale, which is a positive for the individual, and the pre-planned nature mitigates any negative interpretation of insider selling.

Positives

• The exercise of stock options at $21.09 and subsequent sale at significantly higher prices (ranging from $50.595 to $52.67) indicates a profitable transaction for the insider.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, suggesting a planned liquidity event rather than a reaction to recent company news.

Negatives

• The sale of shares by an insider, even if pre-arranged, represents a reduction in their direct equity stake in the company.

Future Outlook

This Form 4 filing reports past insider transactions and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 12, 2024, previously adopted by the Reporting Person.
• The options are vested and currently exercisable.

Industry Context

This filing is a routine disclosure of insider trading activity specific to Akero Therapeutics and its Chief Scientific Officer. It does not provide broader industry trends or competitive analysis.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency into insider stock ownership changes and planned trading activities. The profitable nature of the transaction for the insider may be viewed positively as it reflects value realization.

Key Dates

Keywords

Akero Therapeutics, AKRO, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Timothy Rolph, Chief Scientific Officer, 10b5-1 Plan